Confirmed Objective Response Rate (ORR) of 33% in efficacy-evaluable patients (12 of 36), and a disease control rate (DCR) of 83%
Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of
Faeth Therapeutics (NASDAQ:FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on
Faeth Therapeutics, Inc. (NASDAQ:FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 68,000 shares of the Company’s common
Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end
FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer
Presented
Dr. Schayowitz brings nearly 20 years of oncology drug development experience, including development leadership roles at Pfizer Oncology and Tesaro
Dr. Schayowitz has led dozens of global development programs and led
In two preclinical breast cancer xenograft models (abstract #431P), PIKTOR inhibited tumor growth to a comparable or greater extent than intravenous gedatolisibPIKTOR inhibited HR+/HER2- breast cancer xenograft tumor
Faeth Therapeutics, Inc. (NASDAQ:FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 17,000 shares of the Company’s common
Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancerPoster also includes results from head-to-head
Renowned cancer biologist and Faeth scientific co-founder joins the Board as the Company approaches topline Phase 2 data for PIKTOR in endometrial cancerFaeth Therapeutics, Inc. (NASDAQ:FTH), a clinical-stage
Faeth Therapeutics (NASDAQ:FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader
Faeth Therapeutics (NASDAQ:FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the
Faeth Therapeutics, Inc. (NASDAQ:FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company’s common
— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR
Appointments reinforce technical operations and investor engagement as the company advances its clinical programs
Faeth Therapeutics, Inc. (NASDAQ:FTH) today announced the appointments of Deepak Tiwari as Senior Vice
Faeth Therapeutics, Inc. (NASDAQ:FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Company’s common
